BioTime has formed a new science and technology committee to oversee the development and commercialization of its regenerative medicine and oncology tech.
Newly appointed director and former US FDA commissioner Andrew von Eschenbach joins the three-member committee alongside Optimer Pharmaceuticals CEO Pedro Lichtinger, and Neal Bradsher who is president of Broadwood Capital.
“The committee looks forward to working with the management of BioTime and its subsidiaries in advancing breakthrough products into clinical trials, including those anticipated to begin this year for the use of HyStem-Rx as an implantable matrix for cell delivery in cosmetic and reconstructive surgeries,” said von Eschenbach.
Alfred Kingsley, BioTime chairman, added: “This is an exciting time for the emerging field of regenerative medicine.”
UCB has more than drugs in its 2015 pipeline, while BUPA and biotechs hire new recruits.
Simon Sturge leaves Boehringer Ingelheim to head Merck's biosimilars unit, as well as the European Medicines Agency,...
All change at biopharmas this week, as we reveal the industry movers at four biologics firms. Plus,...
Changes at Novo Nordisk, Questcor, Nicox and more in this week's column.
This week's People on the Move column sees leadership appointments at two major trade bodies, as well...